Segment and Enterprise Wide Disclosures

6 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment and Enterprise Wide Disclosures

Note 11. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. International sales (sales outside the U.S. and primarily in Europe) accounted for 11% and 10% of total product revenue for each of the three and six months ended September 30, 2017, respectively, and 9% of total product revenue for each of the three and six months ended September 30, 2016, respectively. Most of the Company’s long-lived assets are located in the U.S. except for $28.9 million and $23.2 million at September 30, 2017 and March 31, 2017, respectively, which are located primarily in Germany.